Zaki M, Elsherif M, Tawfick W, El Sharkawy M, Hynes N, Sultan S
Western Vascular Institute, Department of Vascular and Endovascular Surgery, University Hospital Galway, National University of Ireland, Galway, Ireland; Vascular Surgery Department, Ain Shams University, Cairo, Egypt.
Western Vascular Institute, Department of Vascular and Endovascular Surgery, University Hospital Galway, National University of Ireland, Galway, Ireland.
Eur J Vasc Endovasc Surg. 2016 Apr;51(4):565-71. doi: 10.1016/j.ejvs.2015.12.025. Epub 2016 Feb 11.
Critical limb ischemia (CLI) is an increasingly alarming presentation of advanced generalized circulatory failure. Most patients presenting with CLI have profound cardiovascular comorbidities that hinder surgical intervention. Moreover, some patients present with non-reconstructable arterial anatomy. For this vulnerable cohort, primary amputation is often the only available option. This study aims at answering the question: Can sequential pneumatic compression (SPC) preclude amputation?
A retrospective analysis of 187 patients (262 limbs) prescribed the Artassist SPC compared outcomes between the group of patients who acquired the device and those who did not. The primary end point was limb salvage; secondary end points were amputation-free survival and improvement in toe pressures.
The mean age was 74.78 years, the median follow-up was 16 months, and the median duration of usage was 4 months. 81.72% of the patient acquired the device and 18.28% did not. The mean toe pressure was 61.4 mmHg pre-application, and 65 mmHg after application (p = .071). Amputation-free survival was 98% and 96% for those who acquired the device and 90% and 84% for those who did not at 6 and 12 months, respectively. There was a non-significant association between limb salvage and device acquisition (p = .714); however, there was a significant improvement in rest pain (p < .0001), reduction in minor amputation (p = .023), and amputation-free survival associated with using the device (p = .01).
Although limb salvage is the paramount ambition for patients referred to vascular services, some patients with CLI are better served with primary amputation. Although the mechanism of SPC action is still ambiguous, there is strong evidence to support its role in preventing minor amputation, prolonging amputation-free survival, and improving rest pain in patients with non-reconstructable CLI; nevertheless, its role in prevention of major amputation lacks statistical significance.
严重肢体缺血(CLI)是晚期全身性循环衰竭中一个日益令人担忧的表现。大多数出现CLI的患者存在严重的心血管合并症,这阻碍了手术干预。此外,一些患者存在无法重建的动脉解剖结构。对于这个脆弱的群体,一期截肢往往是唯一可行的选择。本研究旨在回答以下问题:序贯气压治疗(SPC)能否避免截肢?
对187例患者(262条肢体)使用Artassist SPC进行回顾性分析,比较使用该设备的患者组和未使用该设备的患者组的结局。主要终点是肢体挽救;次要终点是无截肢生存期和趾压改善情况。
平均年龄为74.78岁,中位随访时间为16个月,中位使用时间为4个月。81.72%的患者使用了该设备,18.28%的患者未使用。应用前平均趾压为61.4 mmHg,应用后为65 mmHg(p = 0.071)。使用该设备的患者在6个月和12个月时的无截肢生存率分别为98%和96%,未使用该设备的患者分别为90%和84%。肢体挽救与设备使用之间无显著关联(p = 0.714);然而,静息痛有显著改善(p < 0.0001),小截肢减少(p = 0.023),且使用该设备与无截肢生存期相关(p = 0.01)。
尽管肢体挽救是血管科转诊患者的首要目标,但一些CLI患者进行一期截肢效果更佳。虽然SPC的作用机制仍不明确,但有强有力的证据支持其在预防小截肢、延长无截肢生存期以及改善无法重建的CLI患者静息痛方面的作用;然而,其在预防大截肢方面的作用缺乏统计学意义。